Transcenta Holding Limited (HK:6628) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Transcenta Holding Limited has unveiled promising preclinical results of its novel anti-tumor LIV-1 targeting ADCs, ADC-1 and ADC-2, which showcased significantly higher tumor regression in triple-negative breast cancer models compared to traditional ADCs. These antibodies, utilizing a proprietary site-specific Topoisomerase I Inhibitor payload, demonstrated strong efficacy and potential as next-generation therapeutic agents. This advancement could mark a significant step forward in the treatment of aggressive breast cancer types and other solid tumors.
For further insights into HK:6628 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Broadcom Stock
- ‘Get in for 2025 Gains,’ Says Cowen on Amazon Stock
- Top Analyst Sets the Stage for Nike Stock Ahead of Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
